Αρχική World News Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and Safe...

Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and Safe in Recurrent Glioblastoma

Intratumoural administration of ipilimumab plus nivolumab is safe in patients with resectable and non-resectable recurrent glioblastoma and provides early signs of responses, according to phase I study findings presented at the ESMO Immuno-Oncology Virtual Congress 2020, held from 9 to 12 December 2020.

Intravenous (IV) administration of ipilimumab and nivolumab has demonstrated low activity in patients with recurrent glioblastoma. Leading author Julia K. Schwarze of the Department of Medical Oncology, Universitair Ziekenhuis Brussel in Brussels, Belgium and colleagues evaluated intratumoural and intracavitary (IC) administration of this combination in the phase I GlITIpNi (NCT03233152) clinical study. Previously reported findings from cohorts C1 and C2 of this study showed that intratumoural administration of ipilimumab and nivolumab was safe.1

Cohorts C3 and C4 of the study enrolled 17 patients with non-resectable and 15 patients with resectable recurrent glioblastoma, respectively. All patients underwent intratumoural administration in the brain tissue lining the resection cavity of ipilimumab at 5 mg plus nivolumab at 10 mg that was followed by IC nivolumab through an Ommaya reservoir at three different dose levels of 1, 5, or 10 mg every 2 weeks plus nivolumab 10 mg IV every 2 weeks for a maximum of 12 cycles.

Cerebrospinal fluid (CSF) was collected prior to each drug administration for biochemical and cytological analysis, and concentration measurements of ipilimumab and nivolumab were done. Next generation sequencing (NGS) of RNA and/or DNA and gene expression profiling on resected tissue is ongoing.

Cohorts 3 and 4 comprised 32 patients, of whom 23 were male with a median age of 55 years (range, 38-77); 3 patients had IDH1 R132H mutation and one patient’s tumour showed 1p/19q loss of heterozygosity (LOH).

Clinical benefit following intratumoural delivery of ipilimumab/nivolumab was observed in both cohorts

At time of analysis, all patients had received the predefined intratumoural dose of ipilimumab plus nivolumab and 1 patient remained on treatment. The median number of IC/IV nivolumab administrations was 7.5 (range, 3-12) in C3 dose level 1, 4.5 (range, 1-11) in C3 dose level 2, and 4 (range, 1-8) in C3 dose level 3; patients in C4 received a median of 8 administrations (range, 4-8) in dose level 1, 4.5 administrations (range, 4-8) in dose level 2,  3 administrations (range, 2-12) in dose level 3.  

The most frequently reported adverse events (AEs) were fatigue in 27 patients, headache in 17, fever in 9, and 5 patients had seizures. Only a few low-grade immune-related AEs were observed. Bacterial colonisation of the Ommaya reservoir occurred that required removal of the Ommaya and antibiotic therapy in 4 patients. There were no Grade 5 AEs.

Regarding the C3 cohort, one patient achieved a complete response that was ongoing after 92 weeks. The best response was disease progression (PD) in all of the other 15 evaluable patients.


60 year old female patient with recurrent glioblastoma (IDH1 wild type, MGMT-promotor unmethylated) in cohort 3 (biopsy only) who previously progressed after concomitant radio-/chemotherapy and 4 cycles of chemotherapy with temozolomide achieved a complete response on study treatment that is still ongoing at 92 weeks.

© Julia K. Schwarze.

In the C4 cohort of patients with resectable glioblastoma, 3 patients completed their 24 weeks of treatment.

Progression-free survival and overall survival of cohort C3 and C4 are immature at present.

Five C3 and 6 C4 patients showed elevated protein levels as well as lymphocytic pleocytosis. No evidence for accumulation of ipilimumab or nivolumab was found in the CSF during therapy.

The other analyses, including cytokine levels, cell-free DNA analysis of CSF, and NGS and gene expression profiling on tumour tissue are ongoing.


Based on these findings the authors concluded that intratumoural administration of ipilimumab plus nivolumab followed by IC and IV administration of nivolumab is feasible and sufficiently safe to warrant further investigation in patients with recurrent glioblastoma.

Funding was reported from Stichting Tegen Kanker, “Live for better days” and the Paul De Knop Fonds.


  1. Schwarze JK, et al. ASCO 2020, abstract #2534.


65MO – Schwarze JK, Bertels C, Awada G, et al. A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma. ESMO Immuno-Oncology Virtual Congress 2020 (9-12 December).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...